Binding Commitments Received for a $4 Million Placement
Filed with ASX · · 2 pages · English
• Funds raised under the Placement will be applied towards advancing NTI164 non-clinical toxicology and registration-enabling clinical programs, progressing regulatory submissions, and supporting general working capital. Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Trading Halt
- Neurotech receives $4.73m R&D Tax Incentive Refund
- US FDA Rare Pediatric Disease Designation in Rett syndrome
- Appendix 4E & Annual Report to shareholders
- Positive Human PK Study Results for NTI164
Later from Neurotech International
- Quarterly Activities/Appendix 4C Cash Flow Report
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Positive 90-day GLP toxicology study results in non-rodents
- Appendix 4D & Half Year Report
- NTI initiates First Clinical Site for Phase 3 ASD Trial
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International